

| Flexible Core: Creative Expression | | | | | | | | | | | | | | | | |
|------------------------------------|------------|-------------|------------|-------------|------------|-------------|------------|-------------|------------|-------------|------------|-------------|------------|-------------|------------|-------------|
| Semester | F16 | | S17 | | F17 | | S18 | | F18 | | S19 | | F19 | | S20 | |
| Course | Enrollment | DFWINC Rate | Enrollment | DFWINC Rate | Enrollment | DFWINC Rate | Enrollment | DFWINC Rate | Enrollment | DFWINC Rate | Enrollment | DFWINC Rate | Enrollment | DFWINC Rate | Enrollment | DFWINC Rate |
| AFR 132 | 47 | 4% | 93 | 12% | | | 89 | 8% | | | 79 | 11% | 36 | 8% | 56 | 5% |
| AFR 241 | | | | | | | | | | | 19 | 16% | | | 36 | 8% |
| ART 101 | 241 | 15% | 216 | 22% | 241 | 20% | 237 | 16% | 284 | 13% | 309 | 15% | 282 | 16% | 285 | 14% |
| ART 103 | | | 36 | 3% | | | 35 | 0% | 34 | 0% | 36 | 3% | 35 | 0% | 36 | 0% |
| ART 104 | | | | | | | | | 36 | 17% | | | 36 | 0% | | |
| ART 105 | 169 | 16% | 156 | 9% | 162 | 22% | 126 | 21% | 192 | 13% | 178 | 10% | 229 | 13% | 185 | 12% |
| ART 106 | 61 | 23% | 63 | 10% | 70 | 26% | 49 | 8% | 22 | 9% | 51 | 8% | 36 | 6% | 58 | 12% |
| ART 201 | 80 | 9% | 71 | 14% | 91 | 7% | 77 | 1% | 106 | 12% | 106 | 8% | 107 | 9% | 72 | 0% |
| DRA 110 | 232 | 9% | 197 | 6% | 192 | 7% | 237 | 5% | 177 | 8% | 145 | 8% | 217 | 12% | 169 | 17% |
| DRA 212 | | | 35 | 3% | | | 13 | 15% | | | | | | | 36 | 8% |
| DRA 217 | | | | | 15 | 7% | | | 8 | 0% | | | 14 | 7% | | |
| DRA 225 | 178 | 8% | 203 | 5% | 199 | 9% | 256 | 6% | 226 | 9% | 241 | 12% | 208 | 8% | 191 | 5% |
| ISP 134 | | | 50 | 12% | | | 28 | 21% | | | 25 | 16% | | | 51 | 35% |
| ISP 235 | | | 35 | 9% | | | | | | | 28 | 14% | 32 | 9% | 28 | 11% |
| LIT 106 | 268 | 8% | 218 | 12% | 279 | 22% | 202 | 24% | 243 | 12% | 215 | 17% | 273 | 19% | 226 | 13% |
| LIT 230 | 159 | 24% | 70 | 11% | 134 | 15% | 67 | 22% | 135 | 11% | 79 | 13% | 64 | 14% | 78 | 19% |
| LIT 241 | | | | | 43 | 16% | 57 | 9% | 56 | 9% | 73 | 7% | 39 | 13% | 88 | 9% |
| LLS 110 | 39 | 23% | 32 | 9% | 79 | 19% | 68 | 13% | 89 | 17% | 72 | 17% | 94 | 18% | 55 | 5% |
| LLS 217 | | | | | | | | | 7 | 0% | | | 13 | 8% | | |
| LLS 223 | | | | | 36 | 25% | | | | | | | 15 | 33% | | |
| MHC 125 | 20 | 5% | | | 20 | 0% | | | 20 | 0% | | | 20 | 0% | | |
| MUS 101 | 124 | 20% | 92 | 16% | 157 | 12% | 132 | 20% | 160 | 18% | 117 | 18% | 132 | 9% | 125 | 13% |
| MUS 103 | 129 | 9% | 115 | 10% | 138 | 11% | 118 | 10% | 128 | 18% | 87 | 11% | 120 | 12% | 102 | 11% |
| MUS 104 | 35 | 23% | 34 | 6% | 36 | 14% | 34 | 15% | 36 | 3% | 36 | 14% | 37 | 8% | 36 | 11% |
| PHI 201 | 27 | 19% | 30 | 13% | 59 | 15% | 69 | 20% | 22 | 9% | 56 | 18% | 36 | 0% | 53 | 19% |
| PHI 238 | | | | | | | | | 36 | 11% | 72 | 0% | 61 | 2% | 67 | 10% |

Last updated 11/18/2021 A. Bolesta